Eli Lilly is advancing its Phase 2 clinical trial to test LY3841136 for weight management in obese and overweight adults.

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research ...

People who take GLP-1 drugs like Ozempic can lose weight even if they face disruptions in accessing the medications, which ...

In today's dynamic and volatile market terrain, investors are increasingly drawn to opportunities that promise robust growth ...

You'll get access to an ad-free website with a faster photo browser, the chance to claim free tickets to a host of events ...

Additionally, new board members were brought in to oversee leadership. Among the appointments were Mike Mason, former president of Eli Lilly's diabetes and obesity business. Existing directors Tara ...

WeightWatchers has appointed Dr. Kim Boyd as chief medical officer and announced a new program focused on helping women ...

WeightWatchers announces Dr. Kim Boyd as its new chief medical officer and unveils a program to support women through ...

While Eli Lilly has struggled in the past year due to competitive pressures, the statistical winds may finally favor LLY ...

Business Insider spoke to Eli Lilly's new president of cardiometabolic health, who shared the company's aggressive incretin ...

Eli Lilly’s blockbuster GLP-1 drugs dominate headlines, but its broader portfolio deserves a standing ovation for driving ...

This change is happening because there’s another covered medication that’s safe and effective for your condition and may cost ...